Why the study?
Immune cell function depends on metabolic state, and this study aimed to establish the role of GLUT-1 and PKM2 in the dysregulation of adaptive immunity and inflammation in NSTEMI patients.
Does the GLUT-1/PKM2 metabolic loop contribute to dysregulation of adaptive immunity and inflammation in patients with NSTEMI?
Does the GLUT-1/PKM2 metabolic loop contribute to dysregulation of adaptive immunity and inflammation in patients with NSTEMI?
NSTEMI patients exhibit dysregulation of the GLUT-1/PKM2 metabolic loop in T cells, promoting metainflammation, which can be attenuated in vitro by inhibiting PKM2 or GLUT-1.
Answers are grounded in this paper and cite their sources.
T-cell GLUT-1 upregulation may drive NSTEMI metainflammation; hypothesis-generating for GLUT-1/PKM2 targeting and requires prospective validation.
AIMS: The functional capacity of the immune cells is strongly dependent on their metabolic state and inflammatory responses are characterized by a greater use of glucose in immune cells. This study is aimed to establish the role of glucose metabolism and its players [glucose transporter 1 (GLUT-1) and pyruvate kinase isozyme M2 (PKM2)] in the dysregulation of adaptive immunity and inflammation observed in patients with non-ST-segment elevation myocardial infarction (NSTEMI). METHODS AND RESULTS: We enrolled 248 patients allocated to three groups: NSTEMI patients, chronic coronary syndromes (CCS) patients, healthy subjects (HSs). NSTEMI patients showed higher expression of GLUT-1 and an enhanced glucose uptake in T cells when compared with CCS patients (P < 0.0001; P = 0.0101, respectively) and HSs (P = 0.0071; P = 0.0122, respectively). PKM2 had a prevalent nuclear localization in T lymphocytes in NSTEMI (P = 0.0005 for nuclear vs. cytoplasm localization), while in CCS and HS, it was equally distributed in both compartments. In addition, the nuclear fraction of PKM2 was significantly higher in NSTEMI compared with HS (P = 0.0023). In NSTEMI patients, treatment with Shikonin and Fasentin, which inhibits PKM2 enzyme activity and GLUT-1-mediated glucose internalization, respectively, led to a significant reduction in GLUT-1 expression along with the down-regulation of pro-inflammatory cytokine expression. CONCLUSION: NSTEMI patients exhibit dysregulation of the GLUT-1/PKM2 metabolic loop characterized by nuclear translocation of PKM2, where it acts as a transcription regulator of pro-inflammatory genes. This detrimental loop might represent a new therapeutic target for personalized medicine.
No takes yet. Share an insight, caveat, or question.
Canonico et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: